The stanford prostate cancer calculator: Development and external validation of online nomograms incorporating PIRADS scores to predict clinically significant prostate cancer.
暂无分享,去创建一个
Richard E. Fan | R. Tibshirani | G. Sonn | S. Rais-Bahrami | P. Ghanouni | R. Fan | J. Gordetsky | J. Nix | A. Thong | P. Sprenkle | Leonard N. Chen | Steve R. Zhou | Nancy N. Wang | Katherine J. To’o | K. Amirkhiz
[1] A. Sidana,et al. Racial disparity in the utilization of multiparametric MRI–ultrasound fusion biopsy for the detection of prostate cancer , 2020, Prostate Cancer and Prostatic Diseases.
[2] James D. Murphy,et al. Survival of African American and non‐Hispanic white men with prostate cancer in an equal‐access health care system , 2020, Cancer.
[3] L. Marks,et al. Magnetic Resonance Imaging Guided Biopsy to Evaluate Prostate Cancer Severity in African American Men , 2019 .
[4] D. Margolis,et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. , 2019, European urology.
[5] A. Stenzinger,et al. Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS , 2019, PloS one.
[6] Richard E. Fan,et al. Applying the PRECISION approach in biopsy naïve and previously negative prostate biopsy patients. , 2019, Urologic oncology.
[7] F. Montorsi,et al. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. , 2019, European urology.
[8] Audrey Renson,et al. Predicting Benign Prostate Pathology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Men with a Prior Negative 12-core Systematic Biopsy: External Validation of a Prognostic Nomogram. , 2019, European urology focus.
[9] Douglas K Owens,et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.
[10] D. Margolis,et al. MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis , 2018, The New England journal of medicine.
[11] J. Weinreb,et al. MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and Data System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI. , 2018, AJR. American journal of roentgenology.
[12] E. Messing,et al. Multi‐institutional nomogram predicting benign prostate pathology on magnetic resonance/ultrasound fusion biopsy in men with a prior negative 12‐core systematic biopsy , 2018, Cancer.
[13] A. Rosenkrantz,et al. Prediction of Prostate Cancer Risk Among Men Undergoing Combined MRI-targeted and Systematic Biopsy Using Novel Pre-biopsy Nomograms That Incorporate MRI Findings. , 2017, Urology.
[14] Richard E. Fan,et al. Prostate Magnetic Resonance Imaging Interpretation Varies Substantially Across Radiologists. , 2017, European urology focus.
[15] D. Moses,et al. A multiparametric magnetic resonance imaging‐based risk model to determine the risk of significant prostate cancer prior to biopsy , 2017, BJU international.
[16] M. Roethke,et al. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. , 2017, European urology.
[17] P. Humphrey,et al. Prostate zonal anatomy correlates with the detection of prostate cancer on multiparametric magnetic resonance imaging/ultrasound fusion-targeted biopsy in patients with a solitary PI-RADS v2-scored lesion. , 2017, Urologic oncology.
[18] B. Hadaschik,et al. The Value of PSA Density in Combination with PI‐RADS™ for the Accuracy of Prostate Cancer Prediction , 2017, The Journal of urology.
[19] E. Messing,et al. Perineural invasion by prostate cancer on MR/US fusion targeted biopsy is associated with extraprostatic extension and early biochemical recurrence after radical prostatectomy. , 2017, Human pathology.
[20] P. Humphrey,et al. Negative Multiparametric Magnetic Resonance Imaging of the Prostate Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy. , 2017, Urology.
[21] S. Rais-Bahrami,et al. Factors predicting prostate cancer upgrading on magnetic resonance imaging–targeted biopsy in an active surveillance population , 2017, Cancer.
[22] M. Parmar,et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study , 2018 .
[23] P. Pepe,et al. Transperineal Versus Transrectal MRI/TRUS Fusion Targeted Biopsy: Detection Rate of Clinically Significant Prostate Cancer , 2017, Clinical genitourinary cancer.
[24] S. Das,et al. Developing a new PI-RADS v2-based nomogram for forecasting high-grade prostate cancer. , 2017, Clinical radiology.
[25] D. Georg,et al. Head-to-head comparison of PI-RADS v2 and PI-RADS v1. , 2016, European journal of radiology.
[26] Baris Turkbey,et al. Clinical implications of a multiparametric magnetic resonance imaging based nomogram applied to prostate cancer active surveillance. , 2015, The Journal of urology.
[27] B. Turkbey,et al. Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer , 2014, Cancer.
[28] Baris Turkbey,et al. Comparison of endorectal coil and nonendorectal coil T2W and diffusion‐weighted MRI at 3 Tesla for localizing prostate cancer: Correlation with whole‐mount histopathology , 2014, Journal of magnetic resonance imaging : JMRI.
[29] P. Choyke,et al. Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. , 2013, The Journal of urology.
[30] Mohammad Hassan Murad,et al. Early detection of prostate cancer: AUA Guideline. , 2013, The Journal of urology.
[31] E. Steyerberg,et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. , 2012, European urology.
[32] D. Koulikov,et al. Why I Cannot Find the Prostate? Behind the Subjectivity of Rectal Exam , 2012, ISRN urology.
[33] Ziding Feng,et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. , 2006, Journal of the National Cancer Institute.